DDInter534 DDInter1678
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589) Given diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016. Combining diazepam, a proven effective therapy for acute repetitive seizures
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Diazepam {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sirolimus
Diazepam {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Diazepam {u} (Compound) resembles {v} (Compound) Estazolam
Estazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Diazepam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Diazepam {u} (Compound) resembles {v} (Compound) Clobazam
Clobazam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Diazepam {u} (Compound) resembles {v} (Compound) Quazepam
Quazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Diazepam {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Diazepam {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Diazepam {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Diazepam {u} (Compound) causes {v} (Side Effect) Local reaction
Local reaction {u} (Side Effect) is caused by {v} (Compound) Etonogestrel
Etonogestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Diazepam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Diazepam (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Diazepam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Diazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Diazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Diazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Diazepam (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may lead to a major life threatening interaction when taken with Sirolimus
Diazepam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Sirolimus (Compound)
Diazepam (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Sirolimus (Compound)
Diazepam (Compound) causes Local reaction (Side Effect) and Local reaction (Side Effect) is caused by Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus